Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 19, Issue 6, Pages -Publisher
MDPI
DOI: 10.3390/ijms19061621
Keywords
gamma-secretase; amyloid beta; calcium signaling; drug target discovery; endoplasmic reticulum; inositol 1,4,5-trisphosphate receptor; ion channel; oxidative stress; ryanodine receptor; therapy
Funding
- National Eye Institute [EY014227, EY022774, EY027005]
- National Institute on Aging [AG022550, AG027956]
- National Center for Research Resources
- National Institute of General Medical Sciences of the National Institutes of Health [RR027093]
- Research to Prevent Blindness
- Felix and Carmen Sabates Missouri Endowed Chair in Vision Research
- NATIONAL INSTITUTE ON AGING [P01AG027956] Funding Source: NIH RePORTER
Ask authors/readers for more resources
A major cause underlying familial Alzheimer's disease (AD) are mutations in presenilin proteins, presenilin 1 (PS1) and presenilin 2 (PS2). Presenilins are components of the -secretase complex which, when mutated, can affect amyloid precursor protein (APP) processing to toxic forms of amyloid beta (A). Consequently, presenilins have been the target of numerous and varied research efforts to develop therapeutic strategies for AD. The presenilin 1 gene harbors the largest number of AD-causing mutations resulting in the late onset familial form of AD. As a result, the majority of efforts for drug development focused on PS1 and A. Soon after the discovery of the major involvement of PS1 and PS2 in -secretase activity, it became clear that neuronal signaling, particularly calcium ion (Ca2+) signaling, is regulated by presenilins and impacted by mutations in presenilin genes. Intracellular Ca2+ signaling not only controls the activity of neurons, but also gene expression patterns, structural functionality of the cytoskeleton, synaptic connectivity and viability. Here, we will briefly review the role of presenilins in -secretase activity, then focus on the regulation of Ca2+ signaling, oxidative stress, and cellular viability by presenilins within the context of AD and discuss the relevance of presenilins in AD drug development efforts.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available